Interpace Biosciences Inc
OTC:IDXG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (8.8), the stock would be worth $1.83 (8% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.6 | $1.99 |
0%
|
| 3-Year Average | 8.8 | $1.83 |
-8%
|
| 5-Year Average | 3.8 | $0.8 |
-60%
|
| Industry Average | 23 | $4.77 |
+140%
|
| Country Average | 23.2 | $4.81 |
+142%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Interpace Biosciences Inc
OTC:IDXG
|
55.1m USD | 9.6 | 2.3 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
105.9B USD | 20 | 59.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
72.9B EUR | 12.6 | 14.1 | |
| US |
|
Cigna Corp
NYSE:CI
|
76.6B USD | 0 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.2B EUR | 29.8 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.4B EUR | 16.6 | 22.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 21.2 | 24.1 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.6B USD | 19.8 | 21.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 9.9 | 11 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD | -51 | -27.3 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.6B USD | 15.1 | 14.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Interpace Biosciences Inc
Glance View
Interpace Biosciences, Inc. operates as a bioinformatics company, which engages in the development and commercialization of molecular diagnostic test and pathology services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company’s clinical services provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer in personalized medicine for improved patient diagnosis and management. Through its pharma services, it develops, commercializes and provides molecular and biomarker-based tests and services. Its pharma services provide pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries and advance personalized medicine. The firm has five commercialized molecular diagnostic tests in the marketplace, which include PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR and RespriDx. Its pipeline product includes BarreGEN.
